Quoin Pharmaceuticals
QNRX
1 hedge funds and large institutions have $285K invested in Quoin Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% less capital invested
Capital invested by funds: $286K → $285K (-$258)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$189K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$52K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3K |
QNRX Hedge Fund Activity: Q1 2020 in Review
1 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2020, worth a combined $285K — down 0.09% from $286K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of QNRX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $189K. The largest seller was Wedbush Securities, exiting entirely with an estimated $52K sold.
- 1 institutional investor held Quoin Pharmaceuticals (QNRX) as of Q1 2020, down from 2 in Q4 2019.
- Funds reported $285K of Quoin Pharmaceuticals stock for Q1 2020, down 0.09% quarter-over-quarter.
- 0 funds opened new Quoin Pharmaceuticals positions in Q1 2020 and 1 closed out, a net change of -1 holder.
- The largest Quoin Pharmaceuticals buyer in Q1 2020 was Renaissance Technologies, an estimated $189K added.
- The largest Quoin Pharmaceuticals seller in Q1 2020 was Wedbush Securities, an estimated $52K sold.
Based on aggregated 13F filings for Q1 2020.